CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 148 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $592,002 | +37.3% | 39,705 | +0.8% | 0.00% | 0.0% |
| Q2 2023 | $431,167 | +368.7% | 39,376 | +32.8% | 0.00% | – |
| Q1 2022 | $92,000 | -8.0% | 29,653 | 0.0% | 0.00% | – |
| Q4 2021 | $100,000 | -10.7% | 29,653 | -3.8% | 0.00% | – |
| Q3 2021 | $112,000 | -16.4% | 30,810 | 0.0% | 0.00% | – |
| Q2 2021 | $134,000 | -4.3% | 30,810 | 0.0% | 0.00% | – |
| Q1 2021 | $140,000 | -90.1% | 30,810 | -87.4% | 0.00% | -100.0% |
| Q4 2020 | $1,408,000 | -77.0% | 245,218 | -71.0% | 0.00% | -78.6% |
| Q3 2020 | $6,122,000 | +7188.1% | 845,499 | +3425.3% | 0.01% | – |
| Q2 2020 | $84,000 | +40.0% | 23,984 | -40.7% | 0.00% | – |
| Q1 2020 | $60,000 | -24.1% | 40,413 | 0.0% | 0.00% | – |
| Q4 2019 | $79,000 | -97.9% | 40,413 | -94.5% | 0.00% | -100.0% |
| Q3 2019 | $3,770,000 | -39.3% | 736,185 | -15.1% | 0.01% | -38.5% |
| Q2 2019 | $6,208,000 | -41.3% | 867,044 | +8.8% | 0.01% | -45.8% |
| Q1 2019 | $10,583,000 | +33.8% | 796,943 | -20.7% | 0.02% | +20.0% |
| Q4 2018 | $7,910,000 | -39.2% | 1,005,039 | -14.4% | 0.02% | -25.9% |
| Q3 2018 | $13,015,000 | +2.7% | 1,174,595 | +24.4% | 0.03% | 0.0% |
| Q2 2018 | $12,667,000 | – | 943,885 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |